The Senate Committee on Health, Education, Labor, and Pensions has announced that Novo Nordisk CEO Lars Jorgensen will voluntarily testify about the high U.S. prices for weight loss drugs Ozempic and Wegovy. This decision cancels a scheduled vote to subpoena Novo's president Doug Langa. The hearing will discuss why these drugs are significantly more expensive in the U.S. compared to other countries.